Tehran University of Medical Sciences

Science Communicator Platform

Share By
Tumor-Suppressing and Anti-Angiogenic Activities of a Recombinant Anti-Cd3ϵ Nanobody in Breast Cancer Mice Model Publisher Pubmed



Khatibi AS1 ; Roodbari NH1 ; Majidzadea K2 ; Yaghmaei P1 ; Farahmand L2
Authors

Source: Immunotherapy Published:2019


Abstract

Achievements in cancer immunotherapy require augmentation of a host's anti-tumor immune response for anti-cancer modality. Materials & methods: Different concentrations of recombinant anti-CD3 nanobody were administered at predetermined time intervals during a 24-day treatment period and then expression of angiogenic biomarkers including VEGFR2, MMP9 and CD31, as well as tumor cell proliferation marker ki67, was determined in tumor sections by immunohistochemistry. Furthermore, expression of cytokines was examined in peripheral blood of mice. Results: Based on our results, administration of nanobody could reduce biomarker expression in tumor sections. Tumor growth was also delayed and survival rate was increased in response to nanobody treatment. Moreover, expression of pro-inflammatory cytokines was reduced. Conclusion: In conclusion, we demonstrated that administration of nanobody could effectively suppress angiogenesis as well as tumor growth. © 2019 © 2019 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Evaluation the Potential of Recombinant Anti-Cd3 Nanobody on Immunomodulatory Function, Molecular Immunology (2020)
2. New Approaches in Cancer Immunotherapy: Review Article, Tehran University Medical Journal (2018)
3. Tumor-Associated Macrophages, Nanomedicine and Imaging: The Axis of Success in the Future of Cancer Immunotherapy, Immunotherapy (2017)
Experts (# of related papers)
View all Related Experts
Fatemeh Atyabi (3)
Farshid Noorbakhsh (1)
Other Related Docs
4. Cd73 Specific Sirna Loaded Chitosan Lactate Nanoparticles Potentiate the Antitumor Effect of a Dendritic Cell Vaccine in 4T1 Breast Cancer Bearing Mice, Journal of Controlled Release (2017)
5. For and Against Tumor Microenvironment: Nanoparticle-Based Strategies for Active Cancer Therapy, Materials Today Bio (2025)
6. Nanoimmunoengineering Strategies in Cancer Diagnosis and Therapy, Clinical and Translational Oncology (2023)
7. Immunoregulation by Resveratrol; Implications for Normal Tissue Protection and Tumour Suppression, Clinical and Experimental Pharmacology and Physiology (2023)
8. Cancer Nanomedicine: Special Focus on Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
9. Nanoparticle-Based Immunotherapy of Breast Cancer Using Recombinant Helicobacter Pylori Proteins, European Journal of Pharmaceutics and Biopharmaceutics (2020)
10. Recombinant Nanobody Against Muc1 Tandem Repeats Inhibits Growth, Invasion, Metastasis, and Vascularization of Spontaneous Mouse Mammary Tumors, Molecular Oncology (2022)
11. Silencing of Hif-1Α/Cd73 Axis by Sirna-Loaded Tat-Chitosan-Spion Nanoparticles Robustly Blocks Cancer Cell Progression, European Journal of Pharmacology (2020)
12. Nanoparticles and Targeted Drug Delivery in Cancer Therapy, Immunology Letters (2017)
13. Immunologic Mechanisms of Bcc1 Nanomedicine Synthesized by Nanochelating Technology in Breast Tumor-Bearing Mice: Immunomodulation and Tumor Suppression, Anti-Cancer Agents in Medicinal Chemistry (2024)
14. Identification and in Vitro Characterization of Novel Nanobodies Against Human Granulocyte Colony-Stimulating Factor Receptor to Provide Inhibition of G-Csf Function, Biomedicine and Pharmacotherapy (2017)
15. Harnessing Self-Assembling Peptide Nanofibers to Prime Robust Tumor-Specific Cd8 T Cell Responses in Mice, International Immunopharmacology (2022)
16. Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy, Nanomedicine: Nanotechnology# Biology# and Medicine (2020)